Carna Biosciences, Inc. (TYO:4572)

Market Cap	5.35B
Revenue (ttm)	636.00M
Net Income (ttm)	-2.18B
Shares Out	19.10M
EPS (ttm)	-121.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	48,100
Average Volume	159,045
Open	281.00
Previous Close	284.00
Day's Range	278.00 - 287.00
52-Week Range	220.00 - 482.00
Beta	0.47
RSI	56.79
Earnings Date	May 9, 2025

About Carna Biosciences

Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, Luciferase PPI stable cell lines, kinase assay kits, peptide substrate, mobility shifty assay, and lipid kinase panels. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection assays. It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable smal...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 63
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4572

Financial Performance

In 2024, Carna Biosciences's revenue was 636.00 million, a decrease of -60.86% compared to the previous year's 1.63 billion. Losses were -2.18 billion, 89.1% more than in 2023.